{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T06:34:01Z","timestamp":1791700441732,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"am","delay-in-days":312,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA060207"],"award-info":[{"award-number":["R01DA060207"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA057289"],"award-info":[{"award-number":["R01DA057289"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jad.2024.12.108","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T23:59:05Z","timestamp":1735689545000},"page":"345-352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Trends and characteristics in ketamine use among US adults with and without depression, 2015\u20132022"],"prefix":"10.1016","volume":"373","author":[{"given":"Kevin H.","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Kepner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Cleland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Palamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2024.12.108_bb0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.jad.2024.12.108_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103582","article-title":"No party, no drugs? Use of stimulants, dissociative drugs, and GHB\/GBL during the early COVID-19 pandemic","volume":"102","author":"Bendau","year":"2022","journal-title":"Int. J. Drug Policy"},{"issue":"6","key":"10.1016\/j.jad.2024.12.108_bb0015","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/0897190014525754","article-title":"Ketamine: An Update on Its Abuse","volume":"27","author":"Bokor","year":"2014","journal-title":"J. Pharm. Pract."},{"issue":"4","key":"10.1016\/j.jad.2024.12.108_bb0020","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/add.14866","article-title":"Substance use disorders and risk for treatment resistant depression: a population-based, nested case-control study","volume":"115","author":"Brenner","year":"2020","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.jad.2024.12.108_bb0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54566","article-title":"Tobacco, alcohol, Cannabis, and other drug use in the US before and during the early phase of the COVID-19 pandemic","volume":"6","author":"Compton","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"32","key":"10.1016\/j.jad.2024.12.108_bb0030","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.15585\/mmwr.mm6932a1","article-title":"Mental health, substance use, and suicidal ideation during the COVID-19 pandemic\u2014United States, June 24-30, 2020","volume":"69","author":"Czeisler","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"6","key":"10.1016\/j.jad.2024.12.108_bb0035","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1097\/j.pain.0000000000002473","article-title":"Declines and regional variation in opioid distribution by U.S. hospitals","volume":"163","author":"Eidbo","year":"2022","journal-title":"Pain"},{"issue":"7","key":"10.1016\/j.jad.2024.12.108_bb0040","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.2105\/AJPH.2021.306256","article-title":"COVID-19 and the drug overdose crisis: uncovering the deadliest months in the United States, January\u2013July 2020","volume":"111","author":"Friedman","year":"2021","journal-title":"Am. J. Public Health"},{"issue":"1","key":"10.1016\/j.jad.2024.12.108_bb0045","first-page":"6","article-title":"Ketamine detection in urine samples from patients poisoned by recreational drugs: epidemiologic, clinical, and toxicologic profiles","volume":"35","author":"Gomila Mu\u00f1iz","year":"2023","journal-title":"Emergencias: Revista De La Sociedad Espanola De Medicina De Emergencias"},{"issue":"5","key":"10.1016\/j.jad.2024.12.108_bb0050","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.amepre.2022.05.014","article-title":"Trends in U.S. depression prevalence from 2015 to 2020: the widening treatment gap","volume":"63","author":"Goodwin","year":"2022","journal-title":"Am. J. Prev. Med."},{"issue":"8","key":"10.1016\/j.jad.2024.12.108_bb0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13802","article-title":"Association of Depression with Past-Month Cannabis use among US adults aged 20 to 59 years, 2005 to 2016","volume":"3","author":"Gorfinkel","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/j.jad.2024.12.108_bb0060","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ajad.12866","article-title":"Prescription opioid misuse and comorbid substance use: past 30-day prevalence, correlates and co-occurring behavioral indicators in the 2016 National Survey on drug use and health","volume":"28","author":"Grigsby","year":"2019","journal-title":"Am. J. Addict."},{"issue":"4","key":"10.1016\/j.jad.2024.12.108_bb0065","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01.EEM.0000927188.96828.62","volume":"45","author":"Gussow","year":"2023","journal-title":"The Ketamine Drive-Through. Emergency Medicine News"},{"issue":"7","key":"10.1016\/j.jad.2024.12.108_bb0070","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/10826080701801337","article-title":"Multivariate modeling of club drug use initiation among gay and bisexual men","volume":"43","author":"Halkitis","year":"2008","journal-title":"Subst. Use Misuse"},{"issue":"2\u20133","key":"10.1016\/j.jad.2024.12.108_bb0075","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.drugalcdep.2006.12.028","article-title":"Poly-club-drug use among gay & Bisexual men: a longitudinal analysis","volume":"89","author":"Halkitis","year":"2007","journal-title":"Drug Alcohol Depend."},{"issue":"12","key":"10.1016\/j.jad.2024.12.108_bb0080","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","article-title":"Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2024.12.108_bb0085","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","article-title":"Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States","volume":"75","author":"Hasin","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2024.12.108_bb0090","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jad.2024.04.062","article-title":"Long-term follow-up of participants in ketamine clinical trials for mood disorders","volume":"357","author":"Hurst","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.jad.2024.12.108_bb0095","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2020.165","article-title":"Ketamine treatment for depression: qualitative study exploring patient views","volume":"7","author":"Jilka","year":"2021","journal-title":"BJPsych Open"},{"issue":"1","key":"10.1016\/j.jad.2024.12.108_bb0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/nyas.14688","article-title":"Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction","volume":"1508","author":"Jones","year":"2022","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jad.2024.12.108_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2022.107492","article-title":"Increases in methamphetamine injection among treatment admissions in the U.S","volume":"136","author":"Jones","year":"2023","journal-title":"Addict. Behav."},{"issue":"9","key":"10.1016\/j.jad.2024.12.108_bb0110","first-page":"540","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the Management of Adults with major depressive disorder: section 3. Pharmacological treatments. Canadian journal of psychiatry. Revue Canadienne De","volume":"61","author":"Kennedy","year":"2016","journal-title":"Psychiatrie"},{"issue":"9\u201310","key":"10.1016\/j.jad.2024.12.108_bb0115","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1081\/JA-200066936","article-title":"Patterns of Polydrug use among ketamine injectors in new York City","volume":"40","author":"Lankenau","year":"2005","journal-title":"Subst. Use Misuse"},{"issue":"1","key":"10.1016\/j.jad.2024.12.108_bb0120","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41598-022-04832-9","article-title":"Clinical and behavior characteristics of individuals who used ketamine","volume":"12","author":"Lee","year":"2022","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.jad.2024.12.108_bb0125","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1111\/add.15987","article-title":"Adolescent and adult time trends in US hallucinogen use, 2002-19: any use, and use of ecstasy, LSD and PCP","volume":"117","author":"Livne","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.jad.2024.12.108_bb0130","series-title":"Drug Abuse and Addiction in Medical Illness: Causes, Consequences and Treatment","first-page":"275","article-title":"Depression and substance use","author":"Mackie","year":"2012"},{"issue":"1","key":"10.1016\/j.jad.2024.12.108_bb0135","article-title":"Alcohol use disorder and depressive disorders","volume":"40","author":"McHugh","year":"2019","journal-title":"Alcohol Research\u00a0: Current Reviews"},{"issue":"5","key":"10.1016\/j.jad.2024.12.108_bb0140","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and Esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.12.108_bb0145","series-title":"Monitoring the Future National Survey Results on Drug Use, 1975\u20132023: Overview and Detailed Results for Secondary School Students","author":"Miech","year":"2024"},{"issue":"9752","key":"10.1016\/j.jad.2024.12.108_bb0150","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Drug harms in the UK: a multicriteria decision analysis","volume":"376","author":"Nutt","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2024.12.108_bb0155","doi-asserted-by":"crossref","unstructured":"Palamar, J. J., & Le, A. (2021). Media coverage about medical benefits of MDMA and ketamine affects perceived likelihood of engaging in recreational use. Addict. Res. Theory, 0(0), 1\u20138. doi:https:\/\/doi.org\/10.1080\/16066359.2021.1940972.","DOI":"10.1080\/16066359.2021.1940972"},{"issue":"4","key":"10.1016\/j.jad.2024.12.108_bb0160","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-1330","article-title":"Synthetic cannabinoid use among high school seniors","volume":"140","author":"Palamar","year":"2017","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.jad.2024.12.108_bb0165","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.2105\/AJPH.2021.306486","article-title":"Trends in ketamine use, exposures, and seizures in the United States up to 2019","volume":"111","author":"Palamar","year":"2021","journal-title":"Am. J. Public Health"},{"issue":"1","key":"10.1016\/j.jad.2024.12.108_bb0170","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11606-020-05672-x","article-title":"Extensive underreported exposure to ketamine among electronic dance music party attendees","volume":"36","author":"Palamar","year":"2021","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.jad.2024.12.108_bb0175","doi-asserted-by":"crossref","DOI":"10.1111\/ajad.13259","article-title":"Ketamine use in relation to depressive symptoms among high school seniors","author":"Palamar","year":"2022","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.jad.2024.12.108_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104001","article-title":"Trends in drug use among nightclub and festival attendees in new York City, 2017-2022","author":"Palamar","year":"2023","journal-title":"International Journal of Drug Policy, in press."},{"issue":"7","key":"10.1016\/j.jad.2024.12.108_bb0185","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jamapsychiatry.2023.1423","article-title":"Trends in illicit ketamine seizures in the US from 2017 to 2022","volume":"80","author":"Palamar","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.1016\/j.jad.2024.12.108_bb0190","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1177\/02698811221140006","article-title":"Characteristics of poisonings involving ketamine in the United States, 2019-2021","volume":"37","author":"Palamar","year":"2023","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"key":"10.1016\/j.jad.2024.12.108_bb0195","article-title":"Diversion of undistributed pharmaceutical ketamine in the United States, 2017-2023","author":"Palamar","year":"2024","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jad.2024.12.108_bb0200","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.22942","article-title":"Changes in adult alcohol use and consequences during the COVID-19 pandemic in the US","volume":"3","author":"Pollard","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jad.2024.12.108_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.103976","article-title":"Disruption to Australian heroin, methamphetamine, cocaine and ecstasy markets with the COVID-19 pandemic and associated restrictions","volume":"113","author":"Price","year":"2023","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.jad.2024.12.108_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109150","article-title":"Alcohol and other substance use during the COVID-19 pandemic: a systematic review","volume":"229","author":"Roberts","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jad.2024.12.108_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.113407","article-title":"Psychological factors associated with substance use initiation during the COVID-19 pandemic","volume":"293","author":"Rogers","year":"2020","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2024.12.108_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpr.2021.101978","article-title":"Association of opioid misuse with anxiety and depression: a systematic review of the literature","volume":"84","author":"Rogers","year":"2021","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.jad.2024.12.108_bb0225","series-title":"NSDUH 2022 Methodological Resource Book","author":"SAMHSA","year":"2023"},{"issue":"4","key":"10.1016\/j.jad.2024.12.108_bb0230","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.1016\/j.jad.2024.12.108_bb0235","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/da.22536","article-title":"A review of ketamine abuse and diversion","volume":"33","author":"Sassano-Higgins","year":"2016","journal-title":"Depress. Anxiety"},{"issue":"2","key":"10.1016\/j.jad.2024.12.108_bb0240","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/0706743720970860","volume":"66","author":"Swainson","year":"2021","journal-title":"Can. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2024.12.108_bb0245","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2023.75","article-title":"A systematic review of the print media representation of ketamine treatments for psychiatric disorders","volume":"9","author":"Thornton","year":"2023","journal-title":"BJPsych Open"},{"key":"10.1016\/j.jad.2024.12.108_bb0250","doi-asserted-by":"crossref","unstructured":"Walsh, C. A., Livne, O., Shmulewitz, D., Stohl, M., & Hasin, D. S. (2022). Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002-2019. Addict. Behav. Rep., 16, 100454. doi:https:\/\/doi.org\/10.1016\/j.abrep.2022.100454.","DOI":"10.1016\/j.abrep.2022.100454"},{"issue":"7","key":"10.1016\/j.jad.2024.12.108_bb0255","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1176\/appi.ajp.2017.17020239","article-title":"A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders","volume":"174","author":"Wilkinson","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.12.108_bb0260","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2023.4945","article-title":"The rapidly shifting ketamine landscape in the US","author":"Wilkinson","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2024.12.108_bb0265","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jad.2023.10.066","article-title":"Associations of adolescent substance use and depressive symptoms with adult major depressive disorder in the United States: NSDUH 2016\u20132019","volume":"344","author":"Xu","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.jad.2024.12.108_bb0270","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/02791072.2022.2058896","article-title":"Past-year ketamine use: evidence from a United States population, 2015-2019","volume":"55","author":"Yockey","year":"2023","journal-title":"J. Psychoactive Drugs"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724020962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724020962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T20:42:13Z","timestamp":1740343333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724020962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":54,"alternative-id":["S0165032724020962"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.12.108","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends and characteristics in ketamine use among US adults with and without depression, 2015\u20132022","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.12.108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}